Investment company Athyrium Capital Management, LP (Current Portfolio) buys Recro Pharma Inc during the 3-months ended 2021Q1, according to the most recent filings of the investment company, Athyrium ...

Athyrium Capital Management LP and Neuberger Berman has closed its latest healthcare fund at about $2.025 billion. The limited partners of Athyrium Opportunities Fund III include public and private ...

Athyrium Opportunities Fund LP, a private credit fund which invests in healthcare sector, has closed at $507 million. The Fund, which was oversubscribed, is jointly managed by Neuberger Berman and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NEW YORK--(BUSINESS WIRE)--A consortium of investors led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. today announced they have exited their ...

BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered ...

- Cash runway extended into 2024 with $100 million in notes issued at closing and an additional committed $100 million subject to FDA approval of DaxibotulinumtoxinA for Injection for glabellar lines ...

NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Athyrium Capital Management, LP announced that funds managed by it have sold an aggregate of 1,300,000 common shares of HLS Therapeutics (the “Corporation”) ...

Athyrium Capital Management has raised a $1.2 billion healthcare fund, cash earmarked for investments in commercial-stage healthcare companies. Working with investment manager Neuberger Berman, the ...

GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm focused exclusively on the healthcare sector, today announced that it has ...

Athyrium Funds purchased a portion of the royalties payable to Esperion on Japan net sales of Otsuka’s bempedoic acid products, together with related milestone payments, subject to a cap, for total ...